No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.
Document Type
Article
Publication Date
12-10-2020
Publication Title
Leukemia & lymphoma
Keywords
Hemorrhage; PI3K inhibitor; anticoagulant; antiplatelet; thrombocytopenia
Abstract
The advent of novel B-cell receptor pathway targeting agents like ibrutinib dramatically changed management of B-cell malignancies. However, with concomitant anticoagulation (AC) and antiplatelet (AP) therapy, ibrutinib is associated with increased bleeding. This
Clinical Institute
Cancer
Department
Oncology
Recommended Citation
Barrientos, Jacqueline C; Hillmen, Peter; Salles, Gilles; Sharman, Jeff; Stilgenbauer, Stephan; Gurtovaya, Oksana; Xing, Guan; Ruzicka, Bianca; Bhargava, Pankaj; Ghia, Paolo; and Pagel, John M, "No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib." (2020). Articles, Abstracts, and Reports. 4259.
https://digitalcommons.providence.org/publications/4259
